Clinical Trial Update: The Study of Comparing the Efficacy and Safety of Human Umbilical Cord MSCs and Low-dose IL-2 in the Treatment of LN [Phase 3]

View source ↗

Summary

Phase 3 trial comparing human umbilical cord mesenchymal stem cells with low-dose IL-2 for treatment of systemic lupus erythematosus and lupus nephritis; status…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lupus Nephritis
• Systemic Lupus Erythematosus

Drugs mentioned

• Human Umbilical Cord Mesenchymal Stem Cells
• Low-dose Interleukin-2 (interleukin-2)

Snippet

Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Conditions: Systemic Lupus Erythematosus, Lupus Nephritis | Phase 3 | Status: UNKNOWN